Jumpcan Pharmaceutical Group, located in the Taixing Economic Development Zone, Taixing city, East China's Jiangsu province, was recently included in the top 50 list of comprehensive competitiveness of the traditional Chinese patent medicine industry in 2024.
This was announced at the 17th Health Industry (International) Ecological Conference - 2024 CPEO, which opened on Aug 10 in South China's Hainan province.
The selection affirms the achievements of Jumpcan Pharmaceutical Group in the modernization and internationalization of traditional Chinese medicine or TCM, inspiring it to continue its efforts in cultivating the sector and paving the way for more achievements.
As a listed pharmaceutical company, Jumpcan focuses on Chinese and Western medicine, TCM daily chemicals products and TCM health care products.
Dedicated efforts have been made by the group to continuously conduct the research and development of generic drugs which have a high degree of complexity, as well as high-end preparations and innovative drugs.
The company has also implemented the secondary development of large varieties of TCM, carried out the research and development of improved and innovative Chinese medicine drugs, and is moving to upgrade its quality management system.
An aerial view of Jumpcan Pharmaceutical Group. [Photo/WeChat account: txfabu]